Practical Considerations for Integrating Biosimilars Into Clinical Practice
Megan B. May,(1) PharmD, BCOP, Kate Deen Taucher,(2) PharmD, MHA, BCOP, and Wendy H. Vogel,(3) MSN, FNP, AOCNP®
From (1)Baptist Health Lexington, Lexington, Kentucky; (2)UCHealth Memorial Hospital, Colorado Springs, Colorado; (3)Harborside, Huntington, New York
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Megan B. May, PharmD, BCOP, Baptist Health Lexington, 1700 Nicholasville Road, Lexington, KY 40503.
J Adv Pract Oncol 2021;12(4):431–438 |
© 2021 Harborside™
The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In addition, the OAP must be able to evaluate and successfully navigate factors that may affect the adoption of biosimilars, such as the perceived cost-benefit and clinician and patient acceptance.
For access to the full length article, please sign in